Full Transcript: Quantum-Si Q2 2026 Earnings Call
Quantum-Si (NASDAQ: QSI) announced a delay in the Proteus launch to Q2 2027, attributing it to an additional integrated instrument design cycle for improved readiness and reduced manufacturing risk. The company is implementing cost-saving measures, including a 20% workforce reduction, to align expenses with the revised timeline and maintain critical investments. Quantum-Si reiterates its full-year 2026 guidance of approximately $1 million in revenue and adjusted operating expenses of $98 million or less, while exploring opportunities in the non-human proteomics market.
BlackRock (QSI holder) discloses 4.6M-share, 2.3% beneficial stake in Quantum-Si Inc
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 4,598,208 Class A shares in Quantum-Si Inc. This stake represents 2.3% of the class, with BlackRock holding sole voting and dispositive power over these shares. The filing clarifies that while various clients and funds have economic interests, no single person's interest exceeds five percent of Quantum-Si’s outstanding common shares.
Quantum-Si Faces Nasdaq Noncompliance, Delisting Risk Looms
Quantum-Si (QSI) has received a Nasdaq noncompliance notice because its Class A common stock traded below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance by maintaining a $1.00 closing bid for 10 consecutive business days, with a possible extension or appeal before delisting. Analysts currently have a Buy rating on QSI with a $4.00 price target, despite the company's weak financial performance and bearish technicals, largely supported by improved Proteus execution and a sufficient cash runway.
Quantum-Si (NASDAQ: QSI) warned on Nasdaq $1.00 bid compliance
Quantum-Si Incorporated (NASDAQ: QSI) has received a notice from Nasdaq stating that its Class A common stock no longer meets the minimum $1.00 bid price requirement, having traded below this level for 30 consecutive business days. The company has an initial 180-calendar-day period, until January 19, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Failure to comply could lead to potential delisting, though options like transferring to The Nasdaq Capital Market or implementing a reverse stock split are available.
Branford-based biotech Quantum-Si at risk of Nasdaq delisting, again
Branford-based biotech firm Quantum-Si is once again at risk of being delisted from Nasdaq after its stock fell below the minimum $1 per share requirement for 30 consecutive business days. This marks the second time in less than two years the company has received such a warning. Quantum-Si, which commercializes protein-sequencing technology, has until January 19, 2027, to regain compliance.
Shareholders Can't Ignore US$614k Of Sales By Quantum-Si Insiders
Insiders at Quantum-Si Incorporated sold US$614k worth of stock over the past year, primarily at a higher price than the current market value, suggesting they may have avoided further losses. Despite some insider buying earlier, recent insider selling of US$314k in the last three months, with no corresponding purchases, indicates potential concerns about the stock's valuation. While insiders still own 17% of the company, this selling activity warrants caution for potential investors.
Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale
Quantum-Si (QSI) CEO Jeffrey Hawkins sold $20,996 worth of company stock across two transactions in late June to cover taxes related to vesting restricted stock units. Despite the sale, which occurred at prices between $0.88 and $1.005, Hawkins still directly holds over 3.6 million shares. The stock has seen a 59% decline over the past year, though InvestingPro analysis suggests it may be undervalued.
Quantum-Si Incorporated Class A Actuals & Estimates (NASDAQ:QSI)
This article provides an overview of Quantum-Si Incorporated (NASDAQ: QSI) stock performance, financial actuals, and analyst estimates. It covers stock price movements, historical highs and lows, market capitalization, earnings reports, and future forecasts, along with general company information like dividends and employee numbers.
Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale By Investing.com
Jeffrey Alan Hawkins, CEO of Quantum-Si Inc. (NASDAQ:QSI), sold $20,996 worth of company stock in late June across two transactions. These sales were made to cover taxes related to the vesting of restricted stock units. Despite an overall stock decline, Quantum-Si reported strong Q1 2026 earnings, exceeding revenue and EPS forecasts, and is focusing on expanding its Proteus platform through new partnerships and roadshows.
Quantum-Si CPO John Vieceli sells $28,052 in stock
Quantum-Si's CPO, John Vieceli, sold 30,223 shares of Class A Common Stock for a total of $28,052 across two transactions on June 22 and June 23, 2026. These sales were mandatory to cover withholding taxes for vested restricted stock units. Vieceli still directly owns 1,140,434 shares after these transactions.
Quantum-Si (QSI) CFO offloads 8,233 shares in mandatory tax sell-to-cover
Quantum-Si Inc.'s CFO, Jeffry R. Keyes, sold a total of 8,233 Class A Common Stock shares on June 22nd and 23rd, 2026. These transactions were mandatory "sell-to-cover" sales to meet tax obligations on vested restricted stock units, not discretionary trades. Following these sales, Keyes directly holds 1,724,349 shares of Quantum-Si Class A Common Stock.
Quantum-Si (QSI) CEO Jeffrey Hawkins reports $20,996 stock sale
Quantum-Si (QSI) CEO Jeffrey Hawkins sold company stock totaling $20,996 in late June to cover withholding taxes on restricted stock units. Despite the sales, Hawkins still directly holds over 3.6 million shares. The stock has seen a significant decline, falling 59% in the past year, while the company recently reported exceeding Q1 2026 earnings and revenue expectations, and announced a partnership to enhance its protein sequencing platform.
Quantum-Si GC LaPointe sells $14,468 in company shares
Christian LaPointe, General Counsel of Quantum-Si Inc. (NASDAQ:QSI), sold $14,468 worth of Class A Common Stock across two transactions on June 22 and June 23, 2026. The sales were mandatory "sell-to-cover" provisions for tax withholding due to restricted stock unit vesting. Despite recent stock volatility and a 59% drop over the past year, InvestingPro analysis suggests the stock may be undervalued, and the company recently reported exceeding Q1 2026 earnings expectations and announced a partnership with Cell Signaling Technology.
Quantum-Si (QSI) CEO executes mandatory sell-to-cover on 22,621 vested shares
Quantum-Si Inc.'s President & CEO, Jeffrey Alan Hawkins, executed a mandatory sell-to-cover of 22,621 Class A Common Stock shares to satisfy tax withholding obligations on vested restricted stock units. The sales occurred on June 22 and June 23, 2026, at weighted average prices of $0.9574 and $0.8990 per share, respectively. Following these transactions, Hawkins directly holds 3,669,802 shares.
Form 144 Quantum-Si Inc For: 24 June By Investing.com
The article reports that Quantum-Si Inc. filed Form 144 for June 24, as published by Investing.com. This filing is a notice indicating the intent to sell restricted securities without being registered with the SEC. The article lists relevant financial market data, including various indices, commodities, and stock performances, specific to June 25, 2026.
Form 144 Quantum-Si Inc For: 24 June By Investing.com
This article announces the filing of Form 144 for Quantum-Si Inc. on June 24, as reported by Investing.com. It is a brief, technical notification regarding a financial filing for the company.
Quantum-Si CPO John Vieceli sells $28,052 in stock By Investing.com
John Vieceli, CPO of Quantum-Si Inc (NASDAQ:QSI), sold 30,223 shares of Class A Common Stock for $28,052 in transactions on June 22 and June 23, 2026. These sales were mandatory "sell-to-cover" provisions to satisfy withholding taxes on vested restricted stock units. Vieceli now directly owns 1,140,434 shares; the stock has seen significant volatility and is down 59% over the past year.
Quantum‑Si (NASDAQ: QSI) plans sale of 79,589 RSU shares via Morgan Stanley
Quantum-Si Incorporated (NASDAQ: QSI) has filed a Form 144 to report the intended sale of 79,589 shares of Class A Common Stock. These shares are related to restricted stock unit vesting on June 20, 2026, and represent equity compensation for services rendered. Morgan Stanley Smith Barney LLC is named as the broker for this transaction.
Quantum-Si (QSI) CPO sells 30,223 shares to cover RSU tax withholding
Quantum-Si Inc.'s Chief Product Officer, John S. Vieceli, sold 30,223 shares of Class A Common Stock across two transactions on June 22nd and 23rd, 2026. These sales were mandated by a "sell-to-cover" provision to handle tax obligations from vested restricted stock units, occurring at weighted average prices of $0.9574 and $0.899 per share. Following these transactions, Vieceli still retains a significant holding of 1,140,434 shares in the company.
Quantum-Si (NASDAQ: QSI) files sale notice for 21,676 Class A shares
Quantum-Si (NASDAQ: QSI) has filed a Form 144 notice for the proposed sale of 21,676 Class A common shares, linked to the vesting of Restricted Stock Units on June 20, 2026. The filing also disclosed a prior sale of 74,763 shares by Jeffry Keyes on April 20, 2026. This notice indicates potential insider selling and an upcoming increase in shares available to the market.
Affiliate files sale notice for Quantum‑Si (NASDAQ: QSI)
An affiliate of Quantum-Si (NASDAQ: QSI) has filed a Form 144, indicating proposed sales of Class A common stock. The filing details a Restricted Stock Unit (RSU) vesting of 59,609 shares on June 20, 2026, as equity compensation and reports a prior sale of 167,424 shares by Jeffrey Hawkins on April 20, 2026. This SEC filing serves as a standard insider notice of sale by an affiliate and outlines the securities information and recent transactions.
Quantum‑Si (NASDAQ: QSI) Form 144: 60,425 RSUs vest, resale listed
Quantum-Si Incorporated (NASDAQ: QSI) filed a Form 144 to report a proposed sale of 60,425 shares of Class A Common Stock. This sale is a result of Restricted Stock Unit (RSU) vesting on June 20, 2026, and will be facilitated by Morgan Stanley Smith Barney LLC. The filing indicates a routine equity compensation event, with the actual sale depending on holder decisions and market conditions.
Quantum-Si CPO John Vieceli sells $28,052 in stock
John Vieceli, Chief Product Officer at Quantum-Si Inc. (NASDAQ:QSI), sold 30,223 shares of Class A Common Stock for a total of $28,052 over two transactions on June 22 and June 23, 2026. These sales were mandated by a sell-to-cover provision for withholding taxes on vested restricted stock units. Despite the stock's 59% drop over the past year, InvestingPro analysis suggests the company is currently undervalued, though it faces negative free cash flow.
Quantum-Si (QSI) Form 25: Nasdaq withdrawal of warrants listing
Quantum-Si Inc. (QSI) has filed a Form 25 with the SEC, notifying Nasdaq of the voluntary withdrawal of its warrant class from listing and registration. This action, certified by Nasdaq as compliant with exchange procedures, means less visibility and potentially lower trading volume for the warrants. The filing details the regulatory rules governing such withdrawals and provides key information about the issuer.
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
Quantum-Si (QSI) has announced a partnership with Cell Signaling Technology (CST) to further the analysis of post-translational modifications (PTM) using Quantum-Si's Proteus™ single-molecule protein sequencing platform. The collaboration aims to integrate CST's expertise in PTM detection and enrichment with Quantum-Si's technology to enable site-resolved detection and quantification of proteins and PTMs for research applications. This partnership is expected to accelerate the validation of Proteus™ PTM capabilities and support new methods for interrogating complex biological systems.
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™
Quantum-Si and Cell Signaling Technology (CST) have announced a partnership to advance and validate post-translational modification (PTM) analysis on Quantum-Si's Proteus™ single-molecule protein sequencing platform. The collaboration will integrate CST's expertise in PTM detection and enrichment with Quantum-Si's technology to enable site-resolved detection and quantification of proteins and PTMs. This partnership aims to accelerate the validation of Proteus's PTM capabilities and support new ways of interrogating complex biological systems for research applications.
Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus
Quantum-Si and Cell Signaling Technology (CST) have announced a partnership to advance post-translational modification (PTM) analysis on Quantum-Si's Proteus single-molecule protein sequencing platform. This collaboration will integrate CST's expertise in PTM detection and immunoaffinity enrichment with Quantum-Si's workflows to enable site-resolved detection and quantitation of proteins and PTMs for research applications. The partnership aims to validate Proteus's PTM capabilities by using CST's datasets to refine Quantum-Si's analysis methods and comparing results with orthogonal mass spectrometry data.
Quantum-Si Announces the Expansion of the Proteus Roadshow
Quantum-Si Incorporated announced the expansion of its Proteus roadshow, aimed at educating the market about its Proteus platform for single-molecule protein sequencing. The roadshow has already visited cities in the US and Europe and is scheduled to stop in North Carolina's Research Triangle Park, St. Louis, and Italy in June, in preparation for the Proteus platform's commercial launch. This initiative seeks to increase customer awareness of their proprietary technology.
[Form 4] Quantum-Si Inc Insider Trading Activity
Quantum-Si Inc director Amir Jafri has reported a new stock option grant, receiving the right to purchase 251,185 shares of Class A Common Stock at an exercise price of $0.8539 per share. The options will vest at the company's next annual stockholders meeting, provided continuous service. Following this transaction, Jafri directly holds 115,942 shares of Class A Common Stock.
Director Paula Dowdy receives 251,185 options at Quantum-Si (QSI)
Quantum-Si director Paula Dowdy was granted 251,185 stock options for Class A Common Stock with an exercise price of $0.8539 per share, expiring on May 18, 2036. These options will vest on the date of the company's next annual stockholders meeting, contingent on her continued service. Following this transaction, Dowdy directly owns 269,107 shares of Class A Common Stock.
Quantum-Si (QSI) grants 251K stock options to director Scott Mendel
Quantum-Si Inc. director Scott Mendel was granted 251,185 stock options to purchase Class A Common Stock at an exercise price of $0.8539 per share, expiring on May 18, 2036. These options will vest on the date of the company's next annual stockholders meeting, contingent on his continued service. Following this transaction, Mendel directly holds 141,843 shares of Class A Common Stock and 251,185 options.
Quantum-Si (QSI) director receives 251,185 stock options as equity grant
Quantum-Si Inc. director Ruth A. Fattori was granted 251,185 stock options for Class A Common Stock, with an exercise price of $0.8539 per share and an expiration date of May 18, 2036. These options vest on the date of the company's next annual stockholders meeting, contingent on her continued service. Following this transaction, Fattori directly holds 170,512 shares of Class A Common Stock.
Quantum-Si (QSI) director granted 251,185-share stock option at $0.8539
Quantum-Si Inc. director John P. Kenny was granted a stock option to purchase 251,185 shares of Class A Common Stock at an exercise price of $0.8539 per share. The option expires on May 18, 2036, and the shares will vest on the company's next annual stockholders meeting date, contingent on his continued service. Following this grant, Kenny directly holds 114,285 shares of Class A Common Stock in addition to the new option.
Quantum-Si (QSI) director awarded 251,185 stock options expiring 2036
Quantum-Si Inc. director Charles R. Kummeth was granted 251,185 stock options at an exercise price of $0.8539 per share, expiring on May 18, 2036. The shares underlying these options will vest at the company's next annual stockholders meeting, contingent on his continued service. This award is compensation-related and increases his direct holdings to 855,000 shares of Class A Common Stock in addition to the new options.
Quantum-Si (QSI) director Brigid Makes receives 251,185 stock options grant
Quantum-Si Inc. director Brigid Makes was granted 251,185 stock options to buy Class A Common Stock at an exercise price of $0.8539 per share, expiring May 18, 2036. These options will vest on the date of the company's next annual stockholders meeting, contingent on her continued service. Following this transaction, Ms. Makes directly holds 20,512 shares of Class A Common Stock in addition to the newly granted options.
Quantum-Si (QSI) director awarded 251,185 options at $0.8539 strike
Jonathan M. Rothberg, a director and 10% owner of Quantum-Si Inc., was granted 251,185 stock options at an exercise price of $0.8539 per share. These options vest upon the company's next annual stockholders meeting, subject to his continued service, and expire on May 18, 2036. Following this grant, Rothberg's direct holdings amount to 2,568,443 Class A Common Stock shares, with additional indirect holdings through various LLCs.
Quantum-Si shareholders reelect board, approve auditor and executive pay
Quantum-Si Inc. shareholders reelected all ten director nominees, ratified PricewaterhouseCoopers LLP as their independent auditor, and approved executive compensation during their recent annual meeting. This occurred amidst operational challenges for the company, including a 37% stock price decline over the past year and a 46% revenue decrease, despite exceeding Q1 2026 earnings and revenue expectations.
Quantum-Si shareholders reelect board, approve auditor and executive pay
Quantum-Si Inc. (NASDAQ:QSI) shareholders reelected all ten director nominees, approved PricewaterhouseCoopers LLP as the independent auditor, and endorsed executive compensation at their annual meeting. These decisions come as the company faces operational challenges, including a 37% stock price drop over the past year and a 46% revenue decline, despite recently surpassing Q1 2026 earnings and revenue expectations.
Quantum-Si Inc stock (US7491641091): Q1 2026 earnings spotlight Proteus platform progress
Quantum-Si Inc (QSI) reported its Q1 2026 earnings, emphasizing significant progress in its Proteus platform development and its strategy in proteomics research tools. The company’s focus is on next-generation protein sequencing technology, aiming to create a hardware-consumables-software ecosystem for academic, biopharmaceutical, and clinical research. While the stock's valuation reflects expectations for future growth, the company acknowledges typical risks associated with early-stage life sciences technology firms.
Quantum Si incorporated : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
Quantum-Si Incorporated reported its Q1 2026 earnings, showing a significant decrease in total revenue by 69.4% compared to Q1 2025, primarily due to customers delaying purchases in anticipation of the Proteus platform launch. The company continues to invest heavily in research and development, particularly for the upcoming Proteus next-generation protein sequencing platform, anticipated to launch by the end of 2026. Despite a net loss, the company maintains sufficient liquidity with $190.4 million in cash and marketable securities, expecting these to fund operations for at least the next 12 months.
Quantum-Si (NASDAQ: QSI) Q1 2026 results and Proteus launch plans
Quantum-Si (NASDAQ: QSI) reported its Q1 2026 financial results, with revenues of $258,000 and a net loss of $21.7 million, as the company continues to invest heavily in its Proteus single-molecule protein sequencing system. The company reiterated its full-year 2026 guidance, focusing on the anticipated commercial launch of Proteus by the end of 2026. Quantum-Si maintains a strong cash position of $190.4 million, expected to fund operations into Q2 2028.
Quantum-Si Reports First Quarter 2026 Financial Results and Highlights Proteus™ Development Milestones
Quantum-Si (Nasdaq: QSI) announced its first quarter 2026 financial results, highlighting significant progress in the development of its Proteus™ single-molecule protein sequencing platform. The company achieved automated sequencing on integrated Proteus instruments and expanded market awareness through roadshows, aiming for a commercial launch by the end of 2026. Despite a net loss of $21.7 million, Quantum-Si reiterated its full-year 2026 financial guidance, anticipating a transition year focused on Proteus's successful launch, and reported strong liquidity with $190.4 million in cash and investments.
Quantum-Si Incorporated (QSI) Reports Q1 Loss, Misses Revenue Estimates
Quantum-Si Incorporated (QSI) reported a Q1 loss of $0.1 per share, surpassing the Zacks Consensus Estimate of a $0.12 loss, indicating a 16.67% surprise. However, the company missed revenue estimates, posting $0.26 million against an expected $0.4 million, representing a 35.5% miss. Despite outperforming EPS estimates twice in the last four quarters, QSI's shares have declined 6.4% year-to-date, falling behind the S&P 500's 7.6% gain.
Here's Why We're Watching Quantum-Si's (NASDAQ:QSI) Cash Burn Situation
Quantum-Si (NASDAQ:QSI) has a cash runway of about 20 months based on its current burn rate of US$97m against US$163m in cash. The company's cash burn increased by 5.2% year-on-year, and operating revenue decreased by 20%, raising concerns about its development. Furthermore, its cash burn represents 47% of its market capitalization, suggesting potential significant shareholder dilution if more capital is needed.
Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting
Quantum-Si (Nasdaq: QSI) announced that two customer-authored posters will be presented at the American Association of Cancer Research (AACR) annual meeting from April 17-22, 2026, in San Diego, California. The posters highlight the application of Quantum-Si's single-molecule protein sequencing technology in investigating therapeutics targeting DNA repair enzymes and in high-resolution detection of post-translational modifications (PTMs). The company's CEO, Jeff Hawkins, expressed excitement about the increasing customer data presented at key industry conferences, underscoring the power of their technology and its role in democratizing advanced protein characterization.
Quantum-Si CFO Jeffry Keyes sells $74,815 in company stock.
Quantum-Si CFO Jeffry Keyes sold $74,815 worth of Class A Common Stock over two days in April 2026, representing shares sold to cover withholding taxes from restricted stock unit vesting. Following these mandatory transactions, Mr. Keyes directly holds 1,732,582 shares. The company recently reported mixed Q4 2025 financial results and announced a multi-city roadshow for its Proteus protein sequencing platform.
Quantum-Si (QSI) RSU vesting triggers 187,500-share proposed sale
Quantum-Si Incorporated has filed a Form 144 notice for the proposed sale of 187,500 shares of Class A Common Stock. This sale is linked to the vesting of Restricted Stock Units on April 22, 2026, and is described as equity compensation for services rendered. The filing also reports an earlier sale of 8,655 shares on March 20, 2026, by Morgan Stanley Smith Barney LLC.
Quantum-Si (QSI) CEO sells 167,424 shares in tax-related trades
Quantum-Si's President & CEO, Jeffrey Alan Hawkins, sold a total of 167,424 Class A Common Stock shares in two separate transactions on April 20 and April 21, 2026. These sales were mandatory "sell-to-cover" provisions to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. After these transactions, Hawkins still directly holds 3,692,423 shares of Quantum-Si.
Quantum-Si (QSI) CFO sells 74,763 shares to cover RSU taxes
Quantum-Si Inc.'s Chief Financial Officer, Jeffry R. Keyes, sold a total of 74,763 shares of Class A Common Stock across April 20 and April 21, 2026. These sales were mandatory "sell-to-cover" provisions to satisfy federal, state, and local withholding taxes associated with vesting restricted stock units (RSUs). After these transactions, Keyes directly owns 1,732,582 Class A shares.
RSU sale notice for Quantum-Si (NASDAQ: QSI) — 416,667 Class A shares
Quantum-Si Incorporated has filed a Form 144 notice indicating a proposed sale of 416,667 Class A Common Stock shares related to a Restricted Stock Unit (RSU) vesting event on April 22, 2026. This filing also disclosures a prior sale of 23,777 shares on March 20, 2026. Morgan Stanley Smith Barney LLC is listed as the broker for these transactions.
